TSHA Company Profile and Key Details

TSHA has shown weak momentum, losing -4.53% over the past week and -1.69% over the past quarter, though year-to-date performance is down -15.64%. Short-term trend indicators are mixed aligned (SMA20 -1.36%, SMA50 -8.22%, SMA200 19.99%). The stock’s 14-day RSI is 45.21 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -24.09% below its high and over 335.24% above its low. Average 10-day trading volume of 2.33 million shares is below the 3-month average of 2.82 million, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $1.05 and $6.02. With a market capitalization of about $1.08 billion, Taysha Gene Therapies, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.08). Key stats such as the average daily volume over the past year has been around 2.83 million shares, in line with its 52-week average. Headquartered in Dallas, TX, Taysha Gene Therapies, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean Nolan, the company employs approximately 73 people and listed since September 24, 2020. Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

Taysha Gene Therapies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.13. This means the shares are trading below this model’s fair value.

Taysha Gene Therapies, Inc. has 272.80 million shares outstanding. The public float is 173.43 million shares, elevated short interest at 16.70% of float. This equals 40.78 million shares. The short ratio is 15.11 days. Institutional investors hold 109.5% of the float. Insiders own 11.04%. Session R.A. II holds 8.87 million shares, Nolan Sean P. has 2.91 million shares and Manning Paul B has 2.84 million shares. Over the past six months, insider transactions show net selling. They sold 1.17 million shares across 11 transactions.

Taysha Gene Therapies, Inc. generated EPS of -$0.35 over the past year. Five-year average earnings growth is -63.99%. Wall Street analysts project EPS growth of -10.28% annually over the next five years. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at -$0.10. Next year's EPS is expected at $70.05. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $6.00. The high target offers 209.05% upside. The low target suggests 32.45% downside. The mean target is $10.12. This offers 123.4% upside. Taysha Gene Therapies, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 2.94%. The prior quarter beat by 28.57%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in August 12, 2024.

Taysha Gene Therapies, Inc. trades at a P/E ratio of -16.21, slightly below the S&P 500 average, with a price-to-sales ratio of 173.33 and a price-to-book ratio of 7.4 trading at moderately above to book value. The P/FCF stands at -12.84, also above market averages.

Our AI price prediction model suggests that Taysha Gene Therapies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.32%, with price expected at $4.59 by March 17, 2026, within a range of $4.44 to $4.73 3-Month Outlook: Projected rise of 106.62%, reaching $9.36 by June 01, 2026, with a range of $9.19 to $9.55. 1-Year Outlook: Projected gain of 428.26%, with price at $23.93 by March 03, 2027, within a range of $26.00 to $29.78.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares are down -15.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Taysha Gene Therapies, Inc. trading at a premium to the broader market with a P/E of -16.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.40, suggesting 195.81% upside. Our AI forecast model points to short-term strength (1.32% over two weeks), a medium-term rise (106.62% over three months), and a longer-term gain (428.26% over one year), with expected trading ranges indicating moderate volatility.